Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | ESRRA | P11474 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21787625 | 0.76 | KDM4E (0.49) | DAOGPR35KDM4EALDH1A1HPGD | |
| SCHEMBL21848181 | 0.73 | DAO (0.62) | DAOBRPF1MCL1 | |
| SCHEMBL23797332 | 0.73 | BRPF1 (0.49) | BRPF1 | |
| SCHEMBL21848174 | 0.71 | ESR2 (0.33) | BRPF1 | |
| SCHEMBL21848235 | 0.70 | DAO (0.45) | DAOESRRAKDM4EALDH1A1HPGD | |
| SCHEMBL23411148 | 0.68 | KDM4E (0.36) | KDM4EALDH1A1 | |
| SCHEMBL1238984 | 0.67 | DAO (1.00) | DAOBRPF1KDM4EALDH1A1HPGD | |
| SCHEMBL20284352 | 0.67 | BRPF1 (0.68) | DAOGPR35BRPF1KDM4EALDH1A1 | |
| SCHEMBL31018134 | 0.67 | ALDH1A1 (0.53) | DAOBRPF1KDM4EALDH1A1HPGD | |
| SCHEMBL21977872 | 0.67 | ALDH1A1 (0.53) | DAOBRPF1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640247-B1 | SYK INHIBITOR AND USE METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-11091460-B2 | Syk inhibitor and use method therefor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-08-17 | — | — | US | disclosed |
| CN-110678461-B | Syk inhibitors and methods of use thereof | 正大天晴药业集团股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| US-20200199101-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
| EP-3640247-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-04-22 | — | — | EP | disclosed |
| CN-110678461-A | Syk inhibitors and methods of use thereof | 正大天晴药业集团股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091460-B2 | Syk inhibitor and use method therefor | SYK, BTK, LCK | DAO 3906/4885GPR35 350/4885ESRRA 2312/4885 |
| US-20200199101-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | SYK, BTK, LCK | DAO 3906/4885GPR35 350/4885ESRRA 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.